MGNX MACROGENICS INC
Nasdaq · SEC CIK 1125345 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $129.1K 1 sales by 1 insiders
- Filings on record
- 164 since 2021-07-20, latest 2026-08-20 18:19
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Peters Jeffrey Stuart | GC, Senior VP, Sec | — | $129.1K |
| Smith Beth Ann | VP, Ctrl, Treas | — | — |
| SIEGEL JAY PHILIP | Dir | — | — |
| Spitznagel Thomas | SVP, Technical Ops | — | — |
| Ferrante Karen Jean | Dir | — | — |
| Bonvini Ezio | SVP, CSO, Research | — | — |
| Risser Eric Blasius | Pres, CEO, Dir | — | — |
| Koenig Scott | Dir | — | — |
| Karrels James | SVP, CFO | — | — |
| Jackson Scott Thomas | Dir | — | — |
Transactions 153
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-26 | 2024-02-22 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $0.00 | +26.2K | 35.1K | +295% | $0 |
| D | 2024-02-26 | 2024-02-22 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | F - Tax | $17.11 | -10.1K | 25.0K | -29% | -$173.3K |
| D | 2024-02-26 | 2024-02-22 | MGNX | Bonvini Ezio | SVP, CSO, Research | F - Tax | $17.11 | -9,366 | 100.9K | -8% | -$160.3K |
| D | 2024-02-26 | 2024-02-22 | MGNX | Bonvini Ezio | SVP, CSO, Research | M - OptEx | $0.00 | +28.1K | 110.3K | +34% | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Karrels James | SVP, CFO, Sec | F - Tax | $17.40 | -5,327 | 201.5K | -3% | -$92.7K |
| D | 2024-02-20 | 2024-02-15 | MGNX | Karrels James | SVP, CFO, Sec | M - OptEx | $0.00 | +15.0K | 206.8K | +8% | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $0.00 | +13.3K | 13.3K | New | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | F - Tax | $17.40 | -4,441 | 8,895 | -33% | -$77.3K |
| D | 2024-02-20 | 2024-02-15 | MGNX | Eck Stephen L. | Chief Medical Off | F - Tax | $17.40 | -6,872 | 9,798 | -41% | -$119.6K |
| D | 2024-02-20 | 2024-02-15 | MGNX | Eck Stephen L. | Chief Medical Off | M - OptEx | $0.00 | +16.7K | 16.7K | New | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Bonvini Ezio | SVP, CSO, Research | F - Tax | $17.40 | -5,871 | 82.1K | -7% | -$102.2K |
| D | 2024-02-20 | 2024-02-15 | MGNX | Bonvini Ezio | SVP, CSO, Research | M - OptEx | $0.00 | +16.7K | 88.0K | +23% | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Spitznagel Thomas | SVP, Technical Ops | F - Tax | $17.40 | -5,020 | 8,316 | -38% | -$87.3K |
| D | 2024-02-20 | 2024-02-15 | MGNX | Spitznagel Thomas | SVP, Technical Ops | M - OptEx | $0.00 | +13.3K | 13.3K | New | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Risser Eric Blasius | COO | F - Tax | $17.40 | -5,879 | 65.1K | -8% | -$102.3K |
| D | 2024-02-20 | 2024-02-15 | MGNX | Risser Eric Blasius | COO | M - OptEx | $0.00 | +16.7K | 70.9K | +31% | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Cilinski Lynn | VP, Ctrl, Treas | M - OptEx | $0.00 | +6,668 | 8,591 | +347% | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Cilinski Lynn | VP, Ctrl, Treas | F - Tax | $17.40 | -2,378 | 6,213 | -28% | -$41.4K |
| D | 2024-02-20 | 2024-02-15 | MGNX | Koenig Scott | Pres, CEO, Dir | M - OptEx | $0.00 | +42.3K | 1.09M | +4% | $0 |
| D | 2024-02-20 | 2024-02-15 | MGNX | Koenig Scott | Pres, CEO, Dir | F - Tax | $17.40 | -14.3K | 1.08M | -1% | -$249.7K |
| 2024-02-07 | 2024-02-07 | MGNX | Bonvini Ezio | SVP, CSO, Research | S - Sale | $18.00 | -3,334 | 71.3K | -4% | -$60.0K | |
| DM | 2024-02-07 | 2024-02-05 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | S - Sale+OE | $16.50 | -76.3K | 0 | -100% | -$1.26M |
| DM | 2024-02-07 | 2024-02-05 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $11.11 | +76.3K | 54.4K | New | +$847.4K |
| 2024-02-02 | 2024-02-01 | MGNX | Bonvini Ezio | SVP, CSO, Research | S - Sale | $15.00 | -13.3K | 74.7K | -15% | -$199.7K | |
| 2024-01-22 | 2024-01-19 | MGNX | Bonvini Ezio | SVP, CSO, Research | S - Sale | $12.00 | -13.3K | 88.0K | -13% | -$159.8K | |
| 2023-12-21 | 2023-12-20 | MGNX | Bonvini Ezio | SVP, CSO, Research | S - Sale | $10.08 | -18.9K | 101.3K | -16% | -$190.3K | |
| 2023-10-04 | 2023-10-02 | MGNX | BB BIOTECH AG | 10% | P - Purchase | $4.46 | +150.0K | 9.93M | +2% | +$669.0K | |
| 2023-09-11 | 2023-09-07 | MGNX | BIOTECH TARGET N V | 10% | P - Purchase | $5.26 | +200.0K | 9.78M | +2% | +$1.05M | |
| 2023-09-01 | 2023-08-30 | MGNX | HURWITZ EDWARD | Dir | P - Purchase | $4.91 | +15.0K | 33.1K | +83% | +$73.7K | |
| 2023-03-14 | 2023-03-10 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | S - Sale | $6.03 | -5,372 | 0 | -100% | -$32.4K | |
| D | 2023-02-24 | 2023-02-22 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | F - Tax | $6.55 | -3,378 | 5,372 | -39% | -$22.1K |
| D | 2023-02-24 | 2023-02-22 | MGNX | Peters Jeffrey Stuart | GC, Senior VP | M - OptEx | $0.00 | +8,750 | 8,750 | New | $0 |
| D | 2023-02-24 | 2023-02-22 | MGNX | Bonvini Ezio | SVP, CSO, Research | F - Tax | $6.55 | -3,619 | 120.2K | -3% | -$23.7K |
| D | 2023-02-24 | 2023-02-22 | MGNX | Bonvini Ezio | SVP, CSO, Research | M - OptEx | $0.00 | +9,375 | 123.8K | +8% | $0 |
| 2023-02-16 | 2023-02-14 | MGNX | BB BIOTECH AG | 10% | P - Purchase | $5.07 | +500.0K | 9.58M | +6% | +$2.54M | |
| 2023-01-23 | 2023-01-19 | MGNX | BIOTECH TARGET N V | 10% | P - Purchase | $5.30 | +150.0K | 9.08M | +2% | +$795.0K | |
| M | 2022-12-28 | 2022-12-23+ | MGNX | BB BIOTECH AG | 10% | P - Purchase | $5.75 | +400.0K | 8.93M | +5% | +$2.30M |
| 2022-11-25 | 2022-11-22 | MGNX | BIOTECH TARGET N V | 10% | P - Purchase | $5.96 | +300.0K | 8.53M | +4% | +$1.79M | |
| D | 2022-10-31 | 2022-10-28 | MGNX | Risser Eric Blasius | COO | M - OptEx | $1.51 | +8,500 | 53.5K | +19% | +$12.8K |
| M | 2022-10-25 | 2022-10-21+ | MGNX | BB BIOTECH AG | 10% | P - Purchase | $4.50 | +500.0K | 7.98M | +7% | +$2.25M |
| M | 2022-10-21 | 2022-10-19+ | MGNX | BB BIOTECH AG | 10% | P - Purchase | $3.89 | +454.4K | 7.44M | +7% | +$1.77M |
| 2022-06-17 | 2022-06-15 | MGNX | Karrels James | SVP, CFO, Sec | P - Purchase | $2.47 | +40.0K | 191.8K | +26% | +$98.8K | |
| D | 2022-05-17 | 2022-05-14 | MGNX | Bonvini Ezio | SVP, CSO, Research | M - OptEx | $0.00 | +5,000 | 116.1K | +5% | $0 |
| D | 2022-05-17 | 2022-05-14 | MGNX | Bonvini Ezio | SVP, CSO, Research | F - Tax | $4.16 | -1,666 | 114.4K | -1% | -$6,931 |
| D | 2022-05-17 | 2022-05-16 | MGNX | Koenig Scott | Pres, CEO, Dir | M - OptEx | $1.51 | +53.3K | 1.05M | +5% | +$80.4K |
| D | 2022-03-28 | 2022-03-28 | MGNX | Karrels James | SVP, CFO, Sec | M - OptEx | $1.51 | +8,316 | 151.8K | +6% | +$12.6K |
| D | 2022-03-04 | 2022-03-04 | MGNX | Risser Eric Blasius | COO | M - OptEx | $0.94 | +500 | 45.0K | +1% | +$470 |
| 2021-11-23 | 2021-11-19 | MGNX | BIOTECH TARGET N V | 10% | P - Purchase | $18.50 | +200.0K | 7.28M | +3% | +$3.70M | |
| D | 2021-11-16 | 2021-11-16 | MGNX | Bonvini Ezio | SVP, CSO, Research | M - OptEx | $16.00 | +2,540 | 111.1K | +2% | +$40.6K |
| M | 2021-09-30 | 2021-09-28+ | MGNX | BB BIOTECH AG | 10% | P - Purchase | $20.55 | +200.0K | 6.98M | +3% | +$4.11M |
| M | 2021-09-20 | 2021-09-16+ | MGNX | BB BIOTECH AG | 10% | P - Purchase | $20.60 | +600.0K | 6.88M | +10% | +$12.36M |
| D | 2021-07-20 | 2021-07-16 | MGNX | Spitznagel Thomas | SVP, BPD, Manufacturing | S - Sale+OE | $25.01 | -5,000 | 0 | -100% | -$125.1K |
| D | 2021-07-20 | 2021-07-16 | MGNX | Spitznagel Thomas | SVP, BPD, Manufacturing | M - OptEx | $7.51 | +5,000 | 5,000 | New | +$37.5K |
Purchase Sale Sale after option exercise All abbreviations